Oaktree Acquisition Corp. III Life Sciences 8-K, filed Oct 26, 2026
Oaktree Acquisition Corp. III Life Sciences (OACC)
About this 8-K
Oaktree Acquisition Corp. III Life Sciences filed this 8-K on October 26, 2026, reporting on events of October 23, 2026.
Oaktree Acquisition Corp. III Life Sciences shareholders approved extending its deadline from October 25, 2026 to November 25, 2026, with monthly extensions to May 25, 2027. Holders of 11,331,102 public shares redeemed them for approximately $122,435,287. AI summary
Items reported
- Item 3.02: Unregistered sale of equity
- Item 5.03: Charter or bylaw amendment, or fiscal year change
- Item 5.07: Shareholder vote results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| |
||
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 3.02 | Unregistered Sales of Equity Securities. |
On October 23, 2026, Oaktree Acquisition Corp. III Life Sciences (“OAC”) issued 4,798,758 Class A ordinary shares, par value $0.0001 per share to Oaktree Acquisition Holdings III LS, LLC, a Cayman Islands limited liability company (the “Sponsor”) upon conversion (the “Conversion”) by the Sponsor of its 4,798,758 Class B ordinary shares, par value $0.0001 per. Following the Conversion, the Sponsor is holding 5,382,739 Class A ordinary shares (including 583,981 private placement shares included in the private placement units that the Sponsor purchased from OAC in connection with OAC’s initial public offering) and 1,000 Class B ordinary shares.
The 4,798,758 Class A ordinary shares issued in connection with the Conversion are subject to the same restrictions as applied to the Class B ordinary shares before the Conversion, including, among other things, certain transfer restrictions, waiver of redemption rights and the obligation to vote in favor of an initial business combination as described in OAC’s final prospectus for its initial public offering. The issuance of Class A ordinary shares upon the Conversion was not registered under the Securities Act of 1933, as amended, in reliance on the exemption from registration provided by Section 3(a)(9) thereof.
| Item 5.03 | Amendments to Articles of Association or Bylaws; Change in Fiscal Year. |
On October 23, 2026, OAC held an extraordinary general meeting in lieu of an annual meeting of its shareholders (the “Extension Meeting”), which was originally scheduled for October 16, 2026 and was postponed to October 23, 2026, as described in OAC’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 2, 2026 (as supplemented, the “Extension Proxy Statement”) and the additional definitive proxy materials filed with the SEC on October 16, 2026. At the Extension Meeting, OAC’s shareholders approved an amendment to OAC’s amended and restated memorandum and articles of association (the “Articles Amendment”) to extend the date (the “Termination Date”) by which OAC has to consummate a business combination (a “Business Combination”) from October 25, 2026 (the “Original Termination Date”) to November 25, 2026 (the “Articles Extension Date”) and to allow OAC, without another shareholder vote, to elect to further extend the Termination Date on a monthly basis after the Articles Extension Date, if requested by the Sponsor, for an aggregate extension period of up to seven months after the Original Termination Date, ending no later than May 25, 2027, unless the closing of a Business Combination shall have occurred prior thereto (the “Extension Amendment Proposal”). On October 23, 2026, OAC filed the Articles Amendment with the Registrar of Companies of the Cayman Islands.
The foregoing description is qualified in its entirety by reference to the Articles Amendment, a copy of which is attached as Exhibit 3.1 hereto and is incorporated by reference herein.
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On October 23, 2026, OAC held the Extension Meeting to consider and vote upon the Extension Amendment Proposal and a proposal to adjourn the Extension Meeting to a later date or dates, if necessary or convenient (the “Adjournment Proposal”), each as more fully described in the Extension Proxy Statement. As there were sufficient votes to approve the Extension Amendment Proposal, the Adjournment Proposal was not presented to shareholders.
Holders of 13,958,831 Class A ordinary shares, $0.0001 par value, of OAC and 4,799,758 Class B ordinary shares, $0.0001 par value, of OAC held of record as of September 22, 2026 (the Class A ordinary shares and Class B ordinary shares voting together as one class), the record date for the Extension Meeting, entitled to vote at the Extension Meeting, were present in person or by proxy, representing approximately 76.3% of the voting power of OAC’s ordinary shares as of the record date for the Extension Meeting, and constituting a quorum for the transaction of business.
The voting results for the Extension Amendment Proposal were as follows:
The Extension Amendment Proposal
| For |
Against |
Abstain | ||
| 17,956,072 | 802,517 | 0 |
The Adjournment Proposal
OAC solicited proxies in favor of the Adjournment Proposal, which would have given OAC authority to adjourn the Extension Meeting to solicit additional proxies. As sufficient shares were voted in favor of the Extension Amendment Proposal, this proposal was not voted upon at the Extension Meeting.
In connection with the vote to approve the Articles Amendment, the holders of 11,331,102 Class A ordinary shares, $0.0001 par value, of OAC issued as part of the units initially sold in OAC’s initial public offering (the “Public Shares”) properly exercised their right to redeem their Public Shares (and did not withdraw their redemption) for cash at a redemption price of approximately $10.805 per Public Share, for an aggregate redemption amount of approximately $122,435,287.
3
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits
| Exhibit |
Description | |
| 3.1 | Amendment to Amended and Restated Memorandum and Articles of Association. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
4
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 26, 2026
| OAKTREE ACQUISITION CORP. III LIFE SCIENCES | ||
| By: | /s/ Zaid Pardesi | |
| Name: | Zaid Pardesi | |
| Title: | Chief Executive Officer | |
5
Exhibit 3.1
OAKTREE ACQUISITION CORP. III LIFE SCIENCES
(THE “COMPANY”)
EXTRACT OF THE MINUTES OF THE EXTRAORDINARY GENERAL MEETING IN LIEU
OF ANNUAL MEETING OF THE COMPANY HELD VIRTUALLY AND AT THE OFFICES OF
KIRKLAND & ELLIS LLP LOCATED AT 601 LEXINGTON AVENUE, NEW YORK, NEW
YORK, 10022, UNITED STATES OF AMERICA ON OCTOBER 23, 2026 AT 10:00 A.M. (EASTERN TIME).
The Chairman at the Extraordinary General Meeting in lieu of Annual Meeting of the Company held on 23 October 2026 (the “Meeting”), hereby certifies that this is a true extract of the minutes of the Meeting held in accordance with the amended and restated memorandum and articles of association of the Company then in effect and that the following resolution was duly adopted at the Meeting:
| 1. | SPECIAL RESOLUTION — EXTENSION AMENDMENT |
| 1.1 | Upon motion duly made, seconded and carried, it was RESOLVED as a Special Resolution that: |
| (a) | Article 164(a) of the Memorandum and Articles of Association be deleted in its entirety and replaced with the following new Article 164(a): |
“In the event that the Company does not consummate a Business Combination upon the date which is the later of (i) November 25, 2026 (or such later date up to, and including, May 25, 2027, if applicable under the provisions of this Article 164) and (ii) such later date as may be approved by the Members in accordance with the Articles (in any case, such date being referred to as the “Termination Date”), or such earlier date as the board of Directors may approve, the Company shall (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Fund, including interest earned on the funds held in the Trust Fund and not released for Permitted Withdrawals (less up to $100,000 to pay winding up and dissolution expenses), divided by the number of Public Shares then in issue, which redemption will completely extinguish public Members’ rights as Members (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of OAC’s remaining Members and the Directors, liquidate and dissolve, subject in the case of sub-articles (ii) and (iii), to its obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. In the event that the Company is wound up for any reason prior to the consummation of a Business Combination, the Company shall also be required to follow the procedures outlined in sub-articles (ii) and (iii) of this Article 164(a).
Notwithstanding the foregoing or any other provisions of the Articles, in the event that the Company has not consummated a Business Combination by November 25, 2026, the Company may, without another shareholder vote, elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after November 25, 2026, by resolution of the Directors, if requested by the Sponsor in writing, and upon five days’ advance notice prior to the applicable Termination Date, until May 25, 2027.”
| (b) | Article 164(b) of the Memorandum and Articles of Association be deleted in its entirety and replaced with the following new Article 164(b): |
“If any amendment is made to Article 164(a) that would modify the substance or timing of the Company’s obligation to provide holders of Class A Shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete its initial Business Combination prior to November 25, 2026 (or up to May 25, 2027, if applicable under the provisions of Article 164(a)), or such earlier date as the board of Directors may approve, or with respect to any other provision relating to the rights of holders of Class A Shares, each holder of Public Shares shall be provided with the opportunity to redeem their Public Shares upon the implementation of any such amendment at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Fund, including interest earned on the Trust Fund and not released for Permitted Withdrawals divided by the number of Public Shares then in issue.”
[Signature Page Follows]
| /s/ Zaid Pardesi |
| Zaid Pardesi, Chairman |
| Dated: 23 October 2026 |